Impact of Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Center study


Authors : Sajid Ali; Ayesha Sadia; Shehryar Ahmad

Volume/Issue : Volume 7 - 2022, Issue 2 - February

Google Scholar : http://bitly.ws/gu88

Scribd : https://bit.ly/3JfQS4F

DOI : https://doi.org/10.5281/zenodo.6360864

Due to limited sources in developing countries mostly breast cancer patients usually present in a locally advanced stage with large masses, infected wounds, or ulcers. Nowadays Neoadjuvant chemotherapy is the gold standard for early and locally advanced stage tumor patients as it downstages tumor with the benefit of breast conservation treatment and also kills the micro metastasis to improve survival and also give an insight into the tumor behaviour by assessing its response to chemotherapy. In the current study, 58 patients with localized breast cancer patients enrolled at Hayatabad medical complex Peshawar in the year 2020-21 were assessed for their response to neoadjuvant chemotherapy. Tumor measurements were carried out by baseline TNM staging pathological assessment postsurgery. Complete pathological response was seen in 24.41% (17.24% were stage 2,5.17% were stage 3, partial response was observed in 31.03% (all were stage 3), 17.64% had stable disease(5.17% were stage 2, 20.68% were stage 3), 20% had progressive disease(1.72% were stage 2, 17.24% were stage 3). We found at the end of the study that breast cancers presented in our setup had a higher stage, unpredictable response to chemotherapy; stage 3 was more resistant to chemotherapy.

Keywords : Breast Cancer, chemotherapy, KI67, Progressive disease Tumor.

CALL FOR PAPERS


Paper Submission Last Date
30 - June - 2022

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe